A Study of Disitamab Vedotin With Other Anticancer Drugs in Solid Tumors
Breast Neoplasms · Gastroesophageal Junction Adenocarcinoma · HER2 Low Breast Neoplasms · HER2 Positive Breast Neoplasms · Stomach Neoplasms · Triple Negative Breast Neoplasms · Metastatic Breast Cancer · Metastatic Gastric Cancer · Advanced Breast Cancer · Advanced Gastric Cancer
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
No warning signs right now. That's why the score is 0.
Score over time
- Stage
- Phase 2
- Patients
- 54 (final count)
- Started
- May 20, 2024
- Main results expected
- Jul 28, 2029
- Fully finished
- Jul 28, 2029
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Number of participants with dose limiting toxicities (DLTs) in dose escalation phase
Measured over: Up to 28 days
Number of participants with adverse events (AEs)
Measured over: Through 30 days after the last study treatment; approximately 5 years
Number of participants with laboratory abnormalities
Measured over: Through 30-37 days after the last study treatment: approximately 5 years
Number of participants with dose alterations
Measured over: Through 30-37 days after the last study treatment: approximately 5 years
Objective response rate (ORR) per Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST v1.1) by investigator assessment
Measured over: Approximately 3 years
Changes Tremor has spotted
Show details (technical version)
Score inputs
- none
Raw record changes
- none yet
Trial ID NCT06157892 · record last updated 2026-07-22 · checked 2026-11-09 15:42 UTC